Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia.

Next Previous
Trial Profile

Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Quizartinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 21 Nov 2012 Final results will be reported at the Annual Meeting of the American Society of Hematology in December 2012, according to an Astellas Pharma and Ambit Biosciences media release.
    • 30 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Dec 2009 Results have been presented at the 51st Annual Meeting of the American Society of Hematology (ASH 2009), according to an Ambit Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top